Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series

Table 2

Standard treatments utilized prior to or during the combined metabolic strategy.

Treatment	Patients (n = 10)
Surgery
No biopsy or resection (technically impossible)	1 (10%)
Biopsy but no resection (inoperable or palliative)	2 (20%)
Partial resection	6 (60%)
Total resection	1 (10%)
Repeat resection
Prior to combined metabolic strategy	2 (20%)
During combined metabolic strategy	2 (20%)
Chemoradiation
No chemoradiation	1 (10%)
1 week of palliative radiation	1 (10%)
3–5 weeks of chemoradiation
Completed prior to combined metabolic strategy	2 (20%)
Overlapped with combined metabolic strategy	1 (10%)
6 weeks of chemoradiation
Completed prior to combined metabolic strategy	4 (40%)
Overlapped with combined metabolic strategy	1 (10%)
Mean total radiation dose (Gy)	45.3 +/−19.8
Adjuvant chemotherapy
No chemotherapy	2 (20%)
3–5 cycles of temozolomide chemotherapy
Completed prior to combined metabolic strategy	0
Overlapped with combined metabolic strategy	3 (30%)
6 cycles of temozolomide chemotherapy
Completed prior to combined metabolic strategy	4 (40%)
Overlapped with combined metabolic strategy	1 (10%)
Post-temozolomide chemotherapy (bevacizumab/irinotecan)	2 (20%)
Dexamethasone
No dexamethasone	0
Daily for 1-2 weeks	4 (40%)
Daily for 3-4 weeks	4 (40%)
Daily for 5-6 weeks	2 (20%)

Except for % variables, values are presented as mean +/−standard deviation.